PULMATRIX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-06-30 was 0.00 shares.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-03-31 was 0.00 shares.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2018-12-31 was 0.00 shares.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2018 was 0.00 shares, a 100.00% decline from fiscal 2017.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2017 was 138.43K shares, a 49872.92% increase from fiscal 2016.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2016 was 277.00 shares, a 99.61% decline from fiscal 2015.
- PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2015 was 71.32K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-03-31 | 0.00 shares S-4/A · filed 2026-08-03 | |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | 0.00 shares derived: sum of 4 quarters · filed 2019-08-05 |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-15 | 0.00 shares derived: sum of 4 quarters · filed 2019-05-15 |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | 0.00 shares 10-K · filed 2019-02-19 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | 0.00 shares derived: sum of 4 quarters · filed 2018-11-14 |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | 0.00 shares derived: sum of 4 quarters · filed 2018-08-03 |
| 2018-03-31 | 0.00 shares 10-Q · filed 2018-05-11 | 2.18K shares derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | 138.43K shares 10-K · filed 2018-03-13 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | 138.43K shares derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-06-30 | 2.18K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | 138.43K shares derived: sum of 4 quarters · filed 2017-08-04 |
| 2017-03-31 | 136.25K shares 10-Q · filed 2017-05-05 | 136.53K shares derived: sum of 4 quarters · filed 2017-05-05 |
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | 277.00 shares 10-K · filed 2017-03-10 |
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | 277.00 shares derived: sum of 4 quarters · filed 2016-11-04 |
| 2016-06-30 | 277.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | 612.00 shares derived: sum of 4 quarters · filed 2016-08-04 |
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-05 | 71.32K shares derived: sum of 4 quarters · filed 2016-05-05 |
| 2015-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | 71.32K shares 10-K · filed 2016-03-10 |
| 2015-09-30 | 335.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | 71.32K shares derived: sum of 4 quarters · filed 2016-03-10 |
| 2015-06-30 | 70.99K shares derived: 10-K 12 month − 3 quarters · filed 2016-03-10 | 70.99K shares derived: sum of 4 quarters · filed 2016-03-10 |
| 2015-03-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-06-10 | 0.00 shares 10-K · filed 2015-06-10 |
| 2014-12-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-02-13 | |
| 2014-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-11-13 | |
| 2014-06-30 | 0.00 shares 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |